- Home
- AYTU vs NRXS Comparison
AYTU vs NRXS Comparison
Compare AYTU & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- NRXS
- Stock Information
- Founded
- AYTU N/A
- NRXS 2011
- Country
- AYTU United States
- NRXS United States
- Employees
- AYTU N/A
- NRXS N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- NRXS
- Sector
- AYTU Health Care
- NRXS
- Exchange
- AYTU Nasdaq
- NRXS Nasdaq
- Market Cap
- AYTU 23.0M
- NRXS 25.8M
- IPO Year
- AYTU N/A
- NRXS 2023
- Fundamental
- Price
- AYTU $2.19
- NRXS $2.79
- Analyst Decision
- AYTU Strong Buy
- NRXS Strong Buy
- Analyst Count
- AYTU 3
- NRXS 1
- Target Price
- AYTU $9.17
- NRXS $7.00
- AVG Volume (30 Days)
- AYTU 182.8K
- NRXS 1.1M
- Earning Date
- AYTU 11-13-2025
- NRXS 11-12-2025
- Dividend Yield
- AYTU N/A
- NRXS N/A
- EPS Growth
- AYTU N/A
- NRXS N/A
- EPS
- AYTU N/A
- NRXS N/A
- Revenue
- AYTU $66,382,000.00
- NRXS $3,217,531.00
- Revenue This Year
- AYTU N/A
- NRXS $62.14
- Revenue Next Year
- AYTU $29.12
- NRXS $131.87
- P/E Ratio
- AYTU N/A
- NRXS N/A
- Revenue Growth
- AYTU 1.84
- NRXS 41.93
- 52 Week Low
- AYTU $0.95
- NRXS $1.33
- 52 Week High
- AYTU $2.82
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- AYTU 46.28
- NRXS 42.07
- Support Level
- AYTU $2.23
- NRXS $2.94
- Resistance Level
- AYTU $2.31
- NRXS $3.96
- Average True Range (ATR)
- AYTU 0.12
- NRXS 0.32
- MACD
- AYTU -0.02
- NRXS -0.08
- Stochastic Oscillator
- AYTU 14.04
- NRXS 0.00
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).